ArticlePloS one2012
Oligo- and polymetastatic progression in lung metastasis(es) patients is associated with specific microRNAs.
Article in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 91 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
91 citing papers in PubMed, 198 citations in OpenAlex.
- Phase 3 Multi-Center, Prospective, Randomized Trial Comparing Single-Dose 24 Gy Radiation Therapy to a 3-Fraction SBRT Regimen in the Treatment of Oligometastatic Cancer.International journal of radiation oncology, biology, physics · 2021Trial
- Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer: The ORIOLE Phase 2 Randomized Clinical Trial.JAMA oncology · 2020Trial
- Multimodal Impact of Number of Metastases and Genetic Alterations on Survival in Metastatic Non-Small Cell Lung Cancer.JCO precision oncology · 2026Article
- Insights on Oligometastatic Non-Small-Cell Lung Cancer.Cancers · 2025Review
- Altered CD4 T cell response in oligometatastic non-small cell lung cancer brain metastasis.Acta neuropathologica communications · 2025Article
- Evolving Paradigms in the Treatment of Oligometastatic Pancreatic Ductal Adenocarcinoma.Journal of gastrointestinal cancer · 2025Review
- Prognostic and Predictive Biomarkers of Oligometastatic NSCLC: New Insights and Clinical Applications.JTO clinical and research reports · 2024Review
- From molecular mechanisms of prostate cancer to translational applications: based on multi-omics fusion analysis and intelligent medicine.Health information science and systems · 2024Review
- OligoM-Cancer: A multidimensional information platform for deep phenotyping of heterogenous oligometastatic cancer.Computational and structural biotechnology journal · 2024Article
- Navigating Breast Cancer Oligometastasis and Oligoprogression: Current Landscape and Future Directions.Current oncology reports · 2024Review
- Stereotactic body radiotherapy takes on Lung Oligometastases: Latest breakthroughs.Precision radiation oncology · 2024Review
- Laser assisted pulmonary metastasectomy promises a low local recurrence rate.Scientific reports · 2024Article
- Metastases-directed local therapies (MDT) beyond genuine oligometastatic disease (OMD): Indications, endpoints and the role of imaging.Clinical and translational radiation oncology · 2024Article
- Oligometastasis: Expansion of Curative Treatments in the Field of Oncology.Medicina (Kaunas, Lithuania) · 2023Review
- Oligometastatic Disease (OMD): The Classification and Practical Review of Prospective Trials.Cancers · 2023Review
- Oligometastases: Characterizing the Role of Epigenetic Regulation of Epithelial-Mesenchymal Transition.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023Review
- The pattern of failure after Stereotactic Radiation Therapy (SRT) for oligo-metastases: predictive factors for poly-progression.Journal of cancer research and clinical oncology · 2023Article
- Optimal Definition of Oligometastasis Showing Survival Benefits of Local Therapies during Tyrosine Kinase Inhibitor Treatment.Cancer research and treatment · 2023Article
- The abscopal effect of immune-radiation therapy in recurrent and metastatic cervical cancer: a narrative review.Frontiers in immunology · 2023Review
- Oligometastatic breast cancer and metastasis-directed treatment: an aggressive multimodal approach to reach the cure.Therapeutic advances in medical oncology · 2023Review
31 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum issuedGnerlich, Jennifer [corrected to Gnerlich, Jennifer L]
Authors and funding
18 authors at 3 institutions in 1 country.
Funding
Abstract
rationaleStrategies to stage and treat cancer rely on a presumption of either localized or widespread metastatic disease. An intermediate state of metastasis termed oligometastasis(es) characterized by limited progression has been proposed. Oligometastases are amenable to treatment by surgical resection or radiotherapy.
methodsWe analyzed microRNA expression patterns from lung metastasis samples of patients with ≤ 5 initial metastases resected with curative intent.
resultsPatients were stratified into subgroups based on their rate of metastatic progression. We prioritized microRNAs between patients with the highest and lowest rates of recurrence. We designated these as high rate of progression (HRP) and low rate of progression (LRP); the latter group included patients with no recurrences. The prioritized microRNAs distinguished HRP from LRP and were associated with rate of metastatic progression and survival in an independent validation dataset.
conclusionOligo- and poly- metastasis are distinct entities at the clinical and molecular level.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.